Detail akcie Aytu BioPharma Rg online

Business Summary: Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Financial Summary: BRIEF: For the six months ended 31 December 2025, Aytu Biopharma Inc revenues decreased 11% to $29.1M. Net loss before extraordinary items totaled $8.6M vs. income of $1.8M. Revenues reflect ADHD portfolio segment decrease of 9% to $26.4M, Pediatric portfolio segment decrease of 35% to $2.4M. Net loss reflects Derivative warrant liabilities (loss) ga decrease from $5.9M (income) to $4.5M (expense), Sales.